Filter by: patients
Home > Community Treatment Reports and Side Effects > Dothiepin Treatment Report
What is Dothiepin?

Dothiepin hydrochloride is now known as dosulepin hydrochloride. It is a trycyclic antidepressant and is sold under the international brand names Dopin, Dopress, Dothapax; Dothep; Espin; Idom; Prepadine; Prothiaden; Protiaden; Protiadene; Thaden; Xerenal.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Treat my mood condition(s) 3 0
Prevent migraine 1 1 Efficacy_major
Insomnia 1 0

See all 2 patients currently taking Dothiepin

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Commonly reported side effects, conditions, and hospitalizations associated with Dothiepin

Mild side effects 1

Reported Dosages

  75 mg daily
  1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Dothiepin (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 1   Side effects too severe: 33%
Other 1   Other: 33%
Course of treatment ended 1   Course of treatment ended: 33%

See all 3 patients who’ve stopped taking Dothiepin

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Dothiepin

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Dothiepin

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Dothiepin

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Dothiepin

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Dothiepin

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

Report created on February 11, 2012.